News | September 19, 2025
WIDAPLIK is the first and only FDA-approved triple combination medication for use as an initial therapy in patients likely to need multiple drugs to achieve blood pressure goals
The suite represents a multi-million-dollar investment in equipment upgrades and enhancements to improve the site's capabilities
Piramal Pharma has reported total income of Rs. 1,992.11 crores during the period ended June 30, 2025
The company has posted net profit of Rs. 91.13 crores for the Financial Year ended March 31, 2025
Observations are largely around improvement of procedures and practices
CDMO business delivered high-teen revenue growth for 9MFY25 driven by continued traction in the on-patent commercial manufacturing and generic API business
Consequent to this appointment, Sarosh Shetty ceases to be Interim CEO of ICH.
Piramal Pharma has reported total income of Rs. 2,302.86 crores during the period ended September 30, 2024
Subscribe To Our Newsletter & Stay Updated
